Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

81.15
-3.7600-4.43%
Volume:795.84K
Turnover:64.92M
Market Cap:11.43B
PE:-35.53
High:83.76
Open:83.13
Low:80.75
Close:84.91
52wk High:95.49
52wk Low:22.73
Shares:140.86M
Float Shares:122.00M
Volume Ratio:0.91
T/O Rate:0.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2838
EPS(LYR):-0.0122
ROE:-55.21%
ROA:-8.10%
PB:24.55
PE(LYR):-6,655.46

Loading ...

Movement Alert|Arrowhead Pharmaceuticals Rises 5.89% in Regular Trading, Preliminary Clinical Data for Alzheimer siRNA Drug Disclosed

Market Focus
·
Jun 12

Arrowhead Pharmaceuticals (ARWR) Valuation Check After New Plozasiran And ARO-INHBE Clinical Updates

Simply Wall St.
·
Jun 06

Analysts’ Top Healthcare Picks: Arrowhead Pharmaceuticals (ARWR), Veeva Systems (VEEV)

TIPRANKS
·
Jun 04

Arrowhead Pharmaceuticals joins Jefferies Global Healthcare Conference fireside chat

Reuters
·
Jun 02

Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After New Plozasiran And ARO INHBE Clinical Results

Simply Wall St.
·
May 29

Arrowhead Pharmaceuticals: Buy Rating Reaffirmed as ARO-INHBE Data Strengthen Outlook and $100 Price Target Maintained

TIPRANKS
·
May 28

Arrowhead presents interim results from Phase 1/2a trial of ARO-INHBE

TIPRANKS
·
May 27

Arrowhead posts Phase 1/2a data showing ARO-INHBE cuts liver fat 44% in obese adults

Reuters
·
May 27

Arrowhead presents clinical cardiometabolic data at EAS Congress

TIPRANKS
·
May 27

Arrowhead says study supports no plozasiran dose adjustment in moderate hepatic or moderate-to-severe renal impairment

Reuters
·
May 26

Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94TH European Atherosclerosis Society (Eas) Congress

THOMSON REUTERS
·
May 26

Arrowhead posts EAS case report on plozasiran use in FCS pregnancy

Reuters
·
May 26

How REDEMPLO Launch Momentum And SHASTA Phase 3 Milestones At Arrowhead Pharmaceuticals (ARWR) Has Changed Its Investment Story

Simply Wall St.
·
May 25

Arrowhead’s ARO-C3 Kidney Trial Reaches Completion, Setting Up the Next Catalyst for ARWR Investors

TIPRANKS
·
May 23

Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Black Diamond Therapeutics (BDTX) and Iovance Biotherapeutics (IOVA)

TIPRANKS
·
May 22

Arrowhead Pharmaceuticals (ARWR) Is Up 5.5% After Licensing ARO-PNPLA3 To Madrigal And Filing US$1B Shelf Registration - Has The Bull Case Changed?

Simply Wall St.
·
May 18

Arrowhead Pharmaceuticals Is Maintained at Market Perform by Bernstein

Dow Jones
·
May 14

Arrowhead Pharmaceuticals : Bernstein Raises Target Price to $46 From $35

THOMSON REUTERS
·
May 13

Arrowhead price target raised to $46 from $35 at Bernstein

TIPRANKS
·
May 13

Arrowhead Pharmaceuticals’ Earnings Call: Launch, Losses, Bets

TIPRANKS
·
May 09